Go to Contents
Company History Targeting, Attacking, and Eradicating Cancers®

TOP

Company History

2019
2018
2017
2016
2015
2014
2013
2011
2009
2008
2007
2019

2019

  • 2019.01

    Poster presentation on Phase 1 interim safety data of Pexa-Vec + Imfinzi clinical study at Gastrointestinal Cancers Symposium (GI ASCO)

2018

2018

  • 2018.12

    Poster presentation on safety data of the Phase 1 dose-escalation clinical trial of Pexa-Vec + Yervoy, at European Society for Medical Oncology (ESMO) Immuno-Oncology

  • 2018.11

    IND approved by Therapeutic Goods Administration on Phase 1 study of Pexa-Vec + Libtayo

  • 2018.06

    Poster presentation on Pexa-Vec as a neoadjuvant therapy at American Society of Clinical Oncology (ASCO)

    First patient enrollment in the US in the Phase 1 study of Pexa-Vec + Libtayo

  • 2018.04

    Presentation on pre-clinical data in Renal Cell Carcinoma (RCC) at American Association for Cancer Research Annual Meeting (AACR)

    Poster presentation on clinical data in Renal Cell Carcinoma (RCC) at International Oncolytic Virus Conference (IOVC)

  • 2018.03

    Stretched out additional vaccinia virus related patents in 13 European territories

  • 2018.02

    Approval by Ministry of Food and Drug Safety (MFDS) of South Korea to commence the Phase 1 clinical trial of Pexa-Vec + Libtayo in RCC

    Poster presentation on RCC clinical data at Genitourinary Cancers Symposium (GU ASCO)

  • 2018.01

    Expanded strategic manufacturing collaboration for JX-970

2017

2017

  • 2017.08

    Collaboration with National Cancer Institute of the US for developing Pexa-Vec in combination with immune checkpoint inhibitors

  • 2017.07

    Approval by China NMPA to commence the Phase 3 clinical trial for Pexa-Vec in liver cancer (PHOCUS)

  • 2017.05

    Collaboration with Regeneron Pharmaceuticals for developing Pexa-Vec in combination with immune checkpoint inhibitors.

2015-2016

2016

  • 2016.12

    SillaJen was listed on KOSDAQ

  • 2016.01

    SillaJen announced the first patient enrollment in the global, randomized Phase 3 trial for Pexa-Vec in Advanced Liver Cancer (PHOCUS)

2015

  • 2015.10

    SillaJen was selected by the government of South Korea as the major developer for the project of “Global State-of-the-art technology development for biomedical products"

  • 2015.04

    The US FDA granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer (PHOCUS)

2014

2014

  • 2014.03

    SillaJen acquired Jennerex, Inc., the global leader in oncolytic immunotherapeutics

    Jennerex was an early leader in the oncolytic virus field. Jennerex researchers showed that Pexa-Vec acted in three distinct ways to attack cancer : by infecting and killing cancer cells, by cutting off the blood supply totumors, and by activating the body’s own immune system to fight cancer

2013

2013

  • 2013.05

    US FDA designated Pexa-Vec as an orphan drug

2011

2011

  • 2011.06

    Jennerex initiated Pexa-Vec Phase 2b clinical trial (HEP018) for Liver Cancer

2009

2009

  • 2009.11

    European Medicines Agency (EMA) designated Pexa-Vec as an orphan drug for Liver Cancer

2008

2008 - 2007

  • 2008.08

    Jennerex initiated Pexa-Vec Phase 2a clinical trial (HEP007)

  • 2007.08

    Jennerex completed Pexa-Vec Phase 1 clinical trial (HEP001)